Close Menu

NEW YORK – Guardant Health said Friday that the US Food and Drug Administration has approved its targeted next-generation sequencing liquid biopsy assay, Guardant360 CDx, for tumor mutation profiling in advanced cancer patients with any solid malignant neoplasm.

The agency also approved a companion diagnostic indication for the test to identify non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor alterations who may benefit from treatment with osimertinib (AstraZeneca's Tagrisso).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.